Levodopa response in long‐term bilateral subthalamic stimulation for Parkinson's disease

Panida Piboolnurak, Anthony E. Lang, Andrés M. Lozano, Janis M. Miyasaki, Jean A. Saint‐Cyr, Yu‐Yan W. Poon, William D. Hutchison, Jonathan O. Dostrovsky, Elena Moro

Movement Disorders · 2007 · 141 citations · 28 references

Concepts

TL;DR

STN‑DBS is effective for advanced Parkinson’s disease, yet its impact on levodopa responsiveness remains uncertain. The study examined long‑term levodopa response, overall STN‑DBS efficacy, and whether pre‑operative levodopa responsiveness predicts long‑term DBS benefit in 33 PD patients. Patients underwent UPDRS evaluations pre‑ and post‑operatively under medication, stimulation, and combined conditions. Long‑term STN‑DBS reduced levodopa responsiveness by ~31–32% over 3–5 years, yet independently improved motor and ADL scores by ~35–37% and ~19–27% respectively, lowered anti‑PD medication use by ~40–48%, and pre‑operative levodopa response failed to predict long‑term DBS benefit. © 2007 Movement Disorder Society.

Abstract

Abstract Subthalamic nucleus deep brain stimulation (STN‐DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long‐term STN‐DBS, STN‐DBS efficacy and predictive value of preoperative levodopa response to long‐term DBS benefit in 33 PD patients with bilateral STN‐DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN‐DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti‐PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years. © 2007 Movement Disorder Society

References

28